UBS Group
NNNN

UBS Group’s Anbio Biotechnology NNNN Stock Holding History

UBS Group’s Portfolio NNNN Stock Details NNNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4K Sell
828
-5,511
-87% -$138K ﹤0.01% 8506
2026
Q1 		$163K Buy
6,339
+3,490
+122% +$91.1K ﹤0.01% 6750
2025
Q4 		$85.7K Buy
2,849
+1,889
+197% +$51.9K ﹤0.01% 6980
2025
Q3 		$35.8K Sell
960
-9,735
-91% -$437K ﹤0.01% 7787
2025
Q2 		$339K Buy
10,695
+4,957
+86% +$47.4K ﹤0.01% 6345
2025
Q1 		$42.8K Buy
+5,738
New +$39.2K ﹤0.01% 7698

Other funds holding NNNN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFS
Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.81B AUM 32.31% 1-Year Est. Return

UBS Group's NNNN Position: Q2 2026 in Review

UBS Group reduced its Anbio Biotechnology (NNNN) stake by 87% in Q2 2026, selling an estimated $138K and leaving 828 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #8506.

UBS Group first reported a position in NNNN in Q1 2025 and has held it in 6 quarters since. The position peaked at $339K in Q2 2025. 12 funds tracked by Wall St. Rank hold NNNN as of Q2 2026.

  • UBS Group held 828 shares of Anbio Biotechnology worth $11.4K as of Q2 2026.
  • UBS Group sold 5,511 Anbio Biotechnology shares in Q2 2026, an estimated $138K.
  • Anbio Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8506 holding.
  • UBS Group first reported a position in Anbio Biotechnology in Q1 2025 and has held it in 6 quarters since.
  • UBS Group's Anbio Biotechnology position peaked at $339K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.